<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02387749</url>
  </required_header>
  <id_info>
    <org_study_id>FACULTY OF MEDICINE,CAIRO U</org_study_id>
    <nct_id>NCT02387749</nct_id>
  </id_info>
  <brief_title>Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .</brief_title>
  <official_title>Effect Of Mesenchymal Stem Cells Transfusion on the Peripheral Neuropathy in Diabetic Patients Measured by Nerve Conduction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A debilitating consequence of diabetes mellitus (DM) is neuropathy which globally affects
      between 20 -30% of diabetic patients and up to 50% in other studies. The incidence of
      diabetic neuropathy (DN) is estimated to be up to 45% for type 2 diabetic patients and 59%
      for type 1diabetic patients in USA.(DN) is the most common complication of DM.The
      pathophysiology of DN is promoted by several risk factors: micro vascular disease, neural
      hypoxia, and hyperglycemia-induced effects.At the molecular level, the primary cause of
      diabetic complications is known to be hyperglycemia, which disrupts cellular metabolism by
      the formation of reactive oxygen species (ROS).In the aspect of nerve functions, ROS
      formation increases neuron's susceptibility to damage. In addition, hyperglycemia impedes
      production of angiogenic and neurotrophic growth factors, which are necessary for normal
      function of neurons and glial cells and maintenance of vascular structure.No definitive
      disease-modifying treatments have been to reverse DN. The current treatment focuses on tight
      glycemic control which can reduce potential risk factors for further nerve damage and
      DN-associated pain management.In many studies, deficiency of neurotrophic factors and lack of
      vascular support have been regarded as key factors in the development DN.Mesenchymal stem
      cells (MSCs) are particularly attractive therapeutic agents because of their ability to
      self-renew, differentiate into multi lineage cell types, and locally secrete angiogenic
      cytokines, including basic fibroblast growth factor (bFGF) and vascular endothelial growth
      factor (VEGF) .These factors were reported to prompt neovascularization and have support for
      neural regeneration.It was plausible that MSCs may also be an effective therapeutic agent for
      the DN treatment through the paracrine effects of bFGF (Shibata et al., 2008) and VEGF and
      their potential to differentiate into neural cells such as astrocytes, oligodendrocytes , and
      Schwann cells.The adherent nature of MSCs makes them easy to expand in culture and an
      attractive candidate to use in cell therapy.Therefore, cell therapy has recently emerged as
      an attractive therapeutic strategy to meet the needs of both neurotrophic and vascular
      deficiencies of DN.Proper diagnosis of DN depends on the pattern of sensory loss, reflex
      test, electrodiagnostic studies, and imaging
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives This study will be conducted to investigate the effects of Mesenchymal stem cells
      (MSC) transfusion on diabetic peripheral neuropathy in diabetic patient. (MSCs) have been
      reported to secrete various cytokines that exhibit angiogenic and neuro supportive effects.

      Study Design Experimental interventional study. phase II clinical trial

      Ethical committee approval (was it ethically approved by the department) Internal medicine
      department Yes

      Study Methods

      Population of study &amp; disease condition (e.g women with hepatitis, ………) Diabetic
      patients(type I, type II) with documented peripheral neuropathy as determined by impaired
      nerve conduction

      Inclusion criteria:

      (Type I, type II) diabetic patients age range (18-45) years, with diabetic peripheral
      neuropathy proved by clinical assessment and nerve conduction who did not receive treatment
      for diabetic peripheral neuropathy.

      Exclusion criteria:

      Decompensated cardiac, renal or liver disease. Associated autoimmune diseases Associated
      endocrinal diseases Pregnancy, usage of contraceptive pills or steroids.

      Methodology in details The study will be conducted on patients with diabetic peripheral
      neuropathy collected from internal medicine department(inpatient and out patients, males and
      females)

      All subjects of this study will be submitted to the following :( preparatory visit before
      (MSCs) transfusion visit.)

        -  Thorough clinical assessment as a general assessment of the patient, also assessment of
           diabetes complications especially diabetic neuropathy. This is including full history
           and examinations (e.g., pain, sensory loss, ulcers, sensory level, etc….) this
           preparatory assessment will be done at internal medicine department.

        -  Venous blood will be drawn in the morning after an overnight fast in the pre (MSCs)
           transfusion visit.

      Plasma biochemical blood measurements will be determined by standard laboratory procedures in
      the central lab at clinical pathology department, Kasr Alaini hospital)

        -  Fasting blood glucose level, 2 hours postprandial.

        -  C-peptide.

        -  Hb A1C.

        -  Basic Fibroblast Growth Factor (bFGF), vascular endothelial growth factor (VEGF) by
           ELISA.

        -  Complete blood picture.

        -  Liver functions in the form of ALT, AST

        -  Kidney functions in the form of serum creatinine.

             -  fundus examination

             -  Nerve conduction study at neurophysiology unit.

             -  Bone marrow aspiration of about 90 ml under local anesthesia once at the first
                visit after preparatory visit mentioned before, the patient will be admitted for 12
                hours and will be monitored closely to avoid anaphylaxis (by steroids,
                anti-allergic treatment), if no complication, will be discharged.

      To avoid infection: During bone marrow aspiration, procedure will be done under complete
      aseptic precautions, placed in sterile tubes containing pre-servative-free heparin
      (Sigma-Aldrich, St. Louis, USA) Separation and processing of the sample will be done under
      good manufacture procedure (GMP): Bone Marrow Aspirate (BMA) will be withdrawn under good
      sterilization of the skin in an isolated area. Processing of the sample will be done in the
      laminar air flow; all supplies are disposable and sterile.

      Technique:

      Separation of mononuclear cells:

      The bone marrow aspirate will be diluted at a ratio of 6:1 with phosphate buffer saline (PBS)
      with 2 mM EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer). The MNCs will be separated under
      aseptic conditions using a Ficoll. Hypaque desity gradient (density 1.077, GibcoBRL, Grand
      Islan, NY, USA) by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40
      ml alpha-modi-field Eagle's medium (αMEM), serum free media; mesencult(Mesenchymal stem cell
      culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco
      BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF) (R&amp;D system, Minneapolis, MN) and
      will be incubated at 370 c in a humidified atmosphere containing 5% CO2 (Digirolamo et
      al.1999).after one day ,non adherent cells will be cultured in the presence of Mesenchymal
      media for 3 weeks changed every 1 week (cambrex Bioscience ,Nottingham, uk). After reaching
      80% confluence the MSCs will be placed in 10 ml saline and will be infused intravenously

      Flow cytometry Surface expression of MSCs using anti- (CD271, CD34, CD73, CD90, CD105, CD29)
      monoclonal antibodies (mAbs) will be analyzed using flow cytometry. MSCs (2X105 cells) will
      be suspended in PBS containing 1% BSA and will be stained with flurochrome -conjugated mAbs
      for 20 minutes on ice (anti-mouse mAanti-CD 271, CD34 CD73, CD90, CD105,CD29; BD Bioscience,
      MN, USA).flow cytometric analysis will be performed using a FACSCaliber (BD
      bioscience)equipped with cell Quest software.10000 cells will be passed in front of the laser
      for each sample. Each sample will be analyzed in duplicate. A cut off value at 20% will be
      set to categorize samples as positive.

      Mesenchymal stem cells will be identified by morphology and immunophenotyping in the central
      lab at clinical pathology department, Kasr Alaini hospital( stem cell lab).

      Mesenchymal stem cells transfusion slowly intravenous will be applied after these procedures
      for the patients after taking their approval and informed consent.

      Follow up 3 months after Mesenchymal stem cells transfusion by fasting blood glucose level, 2
      hours postprandial, C-peptide, Hb A1C, (bFGF), (VEGF) and nerve conduction at kasr Alaini
      hospital departments as mentioned before.

      Possible Risk (mention if there is any risk or not) Anaphylaxis Infection

      Primary outcomes (Most important outcomes to be assessed)

      1- Effect of mesenchymal stem cells transfusion on diabetic peripheral neuropathy regarding
      improvement of clinical symptoms like pain, sensory loss and improvement of nerve conduction.

      Secondary outcome parameters (other outcomes to be assessed)

        1. Mesenchymal stem cells being a treatment modality in diabetes complications like
           peripheral neuropathy, to avoid hazards on patients secondary to diabetic peripheral
           neuropathy.

        2. Improving of diabetic condition like lowering of blood glucose level, decrease in
           insulin requirements and improvement of general condition.

      Sample size (number of participants included) 10 diabetic patients with diabetic peripheral
      neuropathy .

      Source of funding (is there any source of funds or not) Faculty Of Medicine, Cairo
      University.

      Time plan (when to start/ when expected to finish/ when to publish) At least 20 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of b-FGF, v-EGF MEASURED BY ELISA</measure>
    <time_frame>zero ( before) , 7 DAYS, 90 days</time_frame>
    <description>measurement of b-FGF and v-EGF MEASURED BY ELISA before (at zero), and after at (7 days, 90) days after stem cell transfusion to measure the effect of stem cell and its role in nerve regeneration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study.</measure>
    <time_frame>base line(zero dya), 90 days after stem cells transfusion.</time_frame>
    <description>Measuring nerve conduction velocities(NCV) in m/sec upper and lower limbs nerves(sensory and motor) lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory upper limb nerves: ulnar nerve as motor and sensory and compare at base line(zero day) and 90 days after stem cells transfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study</measure>
    <time_frame>base line(zero dya), 90 days after stem cells transfusion .</time_frame>
    <description>Measuring nerve conduction latency in msec of upper and lower limbs nerves(sensory and motor) lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory upper limb nerves: ulnar nerve as motor and sensory and compare at base line and 90 days after stem cells transfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.</measure>
    <time_frame>base line(zero dya), 90 days after stem cells transfusion</time_frame>
    <description>Measuring nerve conduction amplitudes in uv of upper and lower limbs nerves(sensory and motor).
lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory .
upper limb nerves: ulnar nerve as motor and sensory. and compare at base line and 90 days after stem cells transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion</measure>
    <time_frame>base line (zero day) and 90 days after stem cells transfusion</time_frame>
    <description>fasting, 2 hours postprandial blood sugar measurement before at base line (zero day) and after (90 days) stem cells transfusion as a follow up and comparing the values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %</measure>
    <time_frame>at base line (zero day) and 90 days after stem cells transfusion</time_frame>
    <description>Blood tests before and after stem cells(90 days) transfusion and comparing the values in percent % which is reflecting the patient blood sugar control in the previous 3 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&amp;D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (Type I, type II) diabetic patients age range (18-45) years, with diabetic peripheral
             neuropathy proved by clinical assessment and nerve conduction who did not receive
             treatment for diabetic peripheral neuropathy.

        Exclusion Criteria:

          -  Decompensated cardiac, renal or liver disease. Associated autoimmune diseases
             Associated endocrinal diseases Pregnancy, usage of contraceptive pills or steroids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Gamal ElDin Saadi, phd</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <reference>
    <citation>Jackson L, Jones DR, Scotting P, Sottile V. Adult mesenchymal stem cells: differentiation potential and therapeutic applications. J Postgrad Med. 2007 Apr-Jun;53(2):121-7. Review.</citation>
    <PMID>17495381</PMID>
  </reference>
  <reference>
    <citation>Keilhoff G, Stang F, Goihl A, Wolf G, Fansa H. Transdifferentiated mesenchymal stem cells as alternative therapy in supporting nerve regeneration and myelination. Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1235-52. Epub 2006 Jun 16.</citation>
    <PMID>16779672</PMID>
  </reference>
  <reference>
    <citation>Kinnaird T, Stabile E, Burnett MS, Epstein SE. Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res. 2004 Aug 20;95(4):354-63. Review.</citation>
    <PMID>15321945</PMID>
  </reference>
  <reference>
    <citation>Morbach S, Lutale JK, Viswanathan V, Möllenberg J, Ochs HR, Rajashekar S, Ramachandran A, Abbas ZG. Regional differences in risk factors and clinical presentation of diabetic foot lesions. Diabet Med. 2004 Jan;21(1):91-5.</citation>
    <PMID>14706061</PMID>
  </reference>
  <reference>
    <citation>Nakae M, Kamiya H, Naruse K, Horio N, Ito Y, Mizubayashi R, Hamada Y, Nakashima E, Akiyama N, Kobayashi Y, Watarai A, Kimura N, Horiguchi M, Tabata Y, Oiso Y, Nakamura J. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes. 2006 May;55(5):1470-7.</citation>
    <PMID>16644707</PMID>
  </reference>
  <reference>
    <citation>Rathur HM, Boulton AJ. Recent advances in the diagnosis and management of diabetic neuropathy. J Bone Joint Surg Br. 2005 Dec;87(12):1605-10. Review.</citation>
    <PMID>16326870</PMID>
  </reference>
  <reference>
    <citation>Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y, Nakamura N, Ota K, Tosaki T, Matsuki T, Nakashima E, Hamada Y, Oiso Y, Nakamura J. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008 Nov;57(11):3099-107. doi: 10.2337/db08-0031. Epub 2008 Aug 26.</citation>
    <PMID>18728233</PMID>
  </reference>
  <reference>
    <citation>Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000 Aug 12;321(7258):412-9.</citation>
    <PMID>10938049</PMID>
  </reference>
  <reference>
    <citation>Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol. 1999 Nov;107(2):275-81.</citation>
    <PMID>10583212</PMID>
  </reference>
  <reference>
    <citation>Dalla Paola L, Faglia E. Treatment of diabetic foot ulcer: an overview strategies for clinical approach. Curr Diabetes Rev. 2006 Nov;2(4):431-47. Review.</citation>
    <PMID>18220646</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>March 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2015</study_first_posted>
  <results_first_submitted>August 11, 2016</results_first_submitted>
  <results_first_submitted_qc>September 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 11, 2017</results_first_posted>
  <last_update_submitted>March 11, 2018</last_update_submitted>
  <last_update_submitted_qc>March 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>dina mohammed riad</investigator_full_name>
    <investigator_title>Assistant Lecturer of Internal Medicine,faculty of medicine,Kasr Al Ainy hospital</investigator_title>
  </responsible_party>
  <keyword>diabetic peripheral neuropathy</keyword>
  <keyword>mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mesenchymal Stem Cells Transfusion in Diabetic Neuropathy</title>
          <description>collection: bone marrow biopsy from iliac crest. Separation of cells:The bone marrow aspirate will be diluted at a ratio of 6:1 with phosphate buffer saline (PBS) with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer). The MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml alpha-modi-field Eagle's medium (αMEM), serum free media; mesencult(Mesenchymal stem cell culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF) (R&amp;D system, Minneapolis, MN) and will be incubated at 37 c in a humidified atmosphere containing 5% CO2.after one day,non adherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every 1 week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and will be infused intravenously. on 2 sessions to the same patient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>blood pressure all patients were normal blood pressure measurement
routine lab investigations were normal to exclude other co-morbidites</population>
      <group_list>
        <group group_id="B1">
          <title>Mesenchymal Stem Cells Transfusion in DPN Patients</title>
          <description>This study was conducted on 10 patients with Diabetic peripheral neuropathy (DPN), 4 females and 6 males</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.20" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of b-FGF, v-EGF MEASURED BY ELISA</title>
        <description>measurement of b-FGF and v-EGF MEASURED BY ELISA before (at zero), and after at (7 days, 90) days after stem cell transfusion to measure the effect of stem cell and its role in nerve regeneration</description>
        <time_frame>zero ( before) , 7 DAYS, 90 days</time_frame>
        <population>b-FGF, V-EGF (pg/ml) measured at zero, 7 days after stem cell transfusion measured by ELISA to measure the effectiveness of stem cells and as an indication for nerve regeneration</population>
        <group_list>
          <group group_id="O1">
            <title>Measurement of b-FGF and v- EGF MEASURED BY ELISA</title>
            <description>measurement of b-FGF and v- EGF MEASURED BY ELISA before (at zero), and after at (7 days, 90) days after stem cell transfusion to measure the effect of stem cell and its role in nerve regeneration</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of b-FGF, v-EGF MEASURED BY ELISA</title>
          <description>measurement of b-FGF and v-EGF MEASURED BY ELISA before (at zero), and after at (7 days, 90) days after stem cell transfusion to measure the effect of stem cell and its role in nerve regeneration</description>
          <population>b-FGF, V-EGF (pg/ml) measured at zero, 7 days after stem cell transfusion measured by ELISA to measure the effectiveness of stem cells and as an indication for nerve regeneration</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>b-FGF ZERO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b-FGF 7 DAYS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b-FGF 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>v- EGF ZERO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428.7" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>v- EGF 7 DAYS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="601.8" spread="141.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>v-EGF 90 DAYS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371.5" spread="121.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study.</title>
        <description>Measuring nerve conduction velocities(NCV) in m/sec upper and lower limbs nerves(sensory and motor) lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory upper limb nerves: ulnar nerve as motor and sensory and compare at base line(zero day) and 90 days after stem cells transfusion</description>
        <time_frame>base line(zero dya), 90 days after stem cells transfusion.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nerve Conduction Velocities of Nerves</title>
            <description>nerve conduction velocities of nerves examined measured in Upper limbs and Lower limbs nerves,motor and sensory
lower limb motor nerves: tibial and common peroneal lower limb sensory nerve : sural nerve
upper limb motor nerve: ulnar nerve upper limb sensory nerve: ulnar nerve
data measured at zero (before stem cell transfusion) and 90 days after stem cell transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Nerve Conduction Velocities of Nerves Affected Measured by Nerve Conduction Study.</title>
          <description>Measuring nerve conduction velocities(NCV) in m/sec upper and lower limbs nerves(sensory and motor) lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory upper limb nerves: ulnar nerve as motor and sensory and compare at base line(zero day) and 90 days after stem cells transfusion</description>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tibial Motor Nerve conduction velocity zero</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tibial motor nerve conduction velocity 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>common peroneal motor nerve velocity at zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>common peroneal motor nerve velocity at 90 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar Motor Nerve conduction velocity at zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar Motor Nerve conduction velocity at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.2" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar sensory Nerve conduction velocity zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar sensory Nerve conduction velocity at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sural Nerve conduction Velocity at zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sural Nerve conduction Velocity at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study</title>
        <description>Measuring nerve conduction latency in msec of upper and lower limbs nerves(sensory and motor) lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory upper limb nerves: ulnar nerve as motor and sensory and compare at base line and 90 days after stem cells transfusion</description>
        <time_frame>base line(zero dya), 90 days after stem cells transfusion .</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nerve Conduction Latency of Nerves</title>
            <description>nerve conduction latency of nerves examined measured in Upper limbs and Lower limbs nerves,motor and sensory lower limb motor nerves: tibial and common peroneal lower limb sensory nerve : sural nerve upper limb motor nerve: ulnar nerve upper limb sensory nerve: ulnar nerve data measured at zero (before stem cell transfusion) and 90 days after stem cell transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Nerve Conduction Latency of Nerves Affected Measured by Nerve Conduction Study</title>
          <description>Measuring nerve conduction latency in msec of upper and lower limbs nerves(sensory and motor) lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory upper limb nerves: ulnar nerve as motor and sensory and compare at base line and 90 days after stem cells transfusion</description>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tibial Motor nerve conduction latency zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tibial Motor nerve conduction latency 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>common peroneal motor nerve latency at zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>common peroneal motor nerve latency at 90 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar Motor Nerve conduction latency at zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar Motor Nerve conduction latency at 90 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar sensory Nerve conduction latency zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar sensory Nerve conduction latency 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sural Nerve conduction latency at zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sural Nerve conduction latency at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.</title>
        <description>Measuring nerve conduction amplitudes in uv of upper and lower limbs nerves(sensory and motor).
lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory .
upper limb nerves: ulnar nerve as motor and sensory. and compare at base line and 90 days after stem cells transfusion</description>
        <time_frame>base line(zero dya), 90 days after stem cells transfusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nerve Conduction Amplitudes of Nerves</title>
            <description>nerve conduction amplitudes of nerves examined measured in Upper limbs and Lower limbs nerves,motor and sensory lower limb motor nerves: tibial and common peroneal, lower limb sensory nerve : sural nerve.
upper limb motor nerve: ulnar nerve motor , upper limb sensory nerve: ulnar nerve sensory data measured at zero (before stem cell transfusion) and 90 days after stem cell transfusion</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Nerve Conduction Amplitude of Nerves Affected Measured by Nerve Conduction Study.</title>
          <description>Measuring nerve conduction amplitudes in uv of upper and lower limbs nerves(sensory and motor).
lower limb nerves : tibial , common peroneal(CP) as motor and sural nerve as sensory .
upper limb nerves: ulnar nerve as motor and sensory. and compare at base line and 90 days after stem cells transfusion</description>
          <units>uv</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tibial Motor nerve Amplitude zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tibial Motor nerve Amplitude at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>common peroneal motor nerve amplitude at zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>common peroneal motor nerve amplitude at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar Motor Nerve conduction amplitude zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar Motor Nerve conduction amplitude at 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar sensory Nerve conduction amplitude zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ulnar sensory Nerve conduction amplitude at 90 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sural Nerve conduction amplitude at zero day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sural Nerve conduction amplitude at 90 day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion</title>
        <description>fasting, 2 hours postprandial blood sugar measurement before at base line (zero day) and after (90 days) stem cells transfusion as a follow up and comparing the values.</description>
        <time_frame>base line (zero day) and 90 days after stem cells transfusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Blood Tests Measured Before and After Stem Cell Transfusion</title>
            <description>Plasma biochemical blood measurements will be determined by standard laboratory procedures in the central lab at clinical pathology department, Kasr Alaini hospital) Fasting blood glucose level, 2 hours postprandial.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Levels of Fasting Blood Sugar and 2 Hours Post Prandial at Base Line ( Zero Day ) and After (90 Days) After Stem Cells Transfusion</title>
          <description>fasting, 2 hours postprandial blood sugar measurement before at base line (zero day) and after (90 days) stem cells transfusion as a follow up and comparing the values.</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>fasting blood sugar zero</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.30" spread="61.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fasting blood sugar 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.70" spread="37.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post postprandial blood sugar Zero</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291.50" spread="106.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post postprandial blood sugar 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190.30" spread="56.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %</title>
        <description>Blood tests before and after stem cells(90 days) transfusion and comparing the values in percent % which is reflecting the patient blood sugar control in the previous 3 months</description>
        <time_frame>at base line (zero day) and 90 days after stem cells transfusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HA1C Measurment Before and Afterr Stem Cell</title>
            <description>as a cumulative effect of patient control we measured HA1C at zero level and 90 days after stem cell transfusion in %</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Levels of Glycated Haemoglobin( HA1C) After Stem Cells Transfusion Measured in Percent %</title>
          <description>Blood tests before and after stem cells(90 days) transfusion and comparing the values in percent % which is reflecting the patient blood sugar control in the previous 3 months</description>
          <units>percent %</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HA1C Level Zero</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HA1C Level 90 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.96" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>monitoring to mainly anaphylaxis and risk of infection which are the main side effects after stem cells infusion were recorded and excluded.
regular follow up monthly up to 3 months recorded without serious side effects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mesenchymal Stem Cells Transfusion in Diabetic Neuropathy</title>
          <description>collection: bone marrow biopsy from iliac crest. Separation of cells:The bone marrow aspirate will be diluted at a ratio of 6:1 with phosphate buffer saline (PBS) with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer). The MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml alpha-modi-field Eagle's medium (αMEM), serum free media; mesencult(Mesenchymal stem cell culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF) (R&amp;D system, Minneapolis, MN) and will be incubated at 37 c in a humidified atmosphere containing 5% CO2.after one day,non adherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every 1 week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and will be infused intravenously. on 2 sessions to the same patient</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>patients are not so co-operative regarding stem cell collection by bone marrow biopsy, Lab requirements for stem cell culture and follow up are limited to the university lab with expensive equipment and kits The sample is small</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dina Mohammed Riad Ebrahim Abdelmagid</name_or_title>
      <organization>Cairo university, faculty of medicine</organization>
      <phone>+201112052600</phone>
      <email>drdina_m@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

